A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 02 Mar 2016
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms AVEREL
- Sponsors Roche
- 14 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 19 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History